about
Amyloidosis and POEMS syndrome.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialPrimary Amyloidosis Presenting as Common Bile Duct Obstruction With CholangitisPrimary systemic amyloidosis as a real diagnostic challenge - case study.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Management of hematological malignancies in patients affected by renal failure.Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis.Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrilsEvaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).AbstractsReasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyBortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effectsQuick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse
P2860
Q33867198-9C674591-3703-4794-9106-120277B42371Q34788381-094A94CB-4F47-4298-934E-D3B9867796B5Q35081363-F1E58077-58A5-4571-9F03-5DC7647C99B0Q35618293-8FCDB86C-16B0-471C-AFFD-84139169E599Q35631725-8E95CA34-C353-42ED-855C-07364609521AQ37676296-45DAE341-8957-499B-849D-B8FDD015B60EQ37854710-82584820-9480-4835-BCA7-CB39399D3D6DQ38652107-17A5FD1F-D1A4-489B-81E8-242D12A838B5Q41009910-711EA92B-2235-4AF1-938B-A8199694328BQ42090197-E338FC8F-3ED5-449E-A375-1D6D75EA2DF2Q47140227-7C935AE8-550F-4AC8-A7A6-F9B578083046Q47679443-F33107E2-534C-4A28-9EDA-2956AFDB992DQ47727308-12A66C5F-6A5F-4518-8797-1B08B9D582F2Q57259399-A5676A51-31C6-46EF-A395-E23D42CFE11BQ58030096-D82F4125-2E89-49E3-8AEC-9C6AD692E128Q58030146-A8BE8344-1918-46A6-979B-1856FA409302Q58262875-3866CF99-FD19-40DD-9849-04078441D8F9
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Current treatment of AL amyloidosis.
@en
Current treatment of AL amyloidosis.
@nl
type
label
Current treatment of AL amyloidosis.
@en
Current treatment of AL amyloidosis.
@nl
prefLabel
Current treatment of AL amyloidosis.
@en
Current treatment of AL amyloidosis.
@nl
P2860
P1433
P1476
Current treatment of AL amyloidosis.
@en
P2860
P304
P356
10.3324/HAEMATOL.2009.008912
P577
2009-08-01T00:00:00Z